Recombinant Canine PD-1 Fc Chimera Protein, CF

Catalog #: 10553-PD Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
10553-PD-100

Recombinant Canine PD-1 Fc Chimera Protein Binding Activity.

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Canine PD-1 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Canine PD-1 Fc Chimera (Catalog # 10553-PD) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Canine PD-L1/B7-H1 Fc Chimera binds with an ED₅₀ of 0.08-6.4 µg/mL.

Source

Human embryonic kidney cell, HEK293-derived canine PD-1 protein

Canine PD-1 (Leu25-Gly168) Accession # NP_001301026.1	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

NP_001301026.1

N-terminal Sequence
Analysis

Leu25

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

43 kDa

SDS-PAGE

55-70 kDa, under reducing conditions

Product Datasheets

10553-PD

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10553-PD

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Canine PD-1 Fc Chimera (Catalog # 10553-PD) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Canine PD-L1/B7-H1 Fc Chimera binds with an ED₅₀ of 0.08-6.4 µg/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Canine PD-1 Fc Chimera (Catalog#10553-PD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 50-70 kDa and 100-140 kDa, respectively.

Reconstitution Calculator

Background: PD-1

Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). Mature canine PD-1 consists of an extracellular region (ECD) with one immunoglobulin-like V‑type domain, a transmembrane domain, and a cytoplasmic region. The mature ECD of canine PD-1 shares 70% and 57% amino acid sequence identity with human and mouse PD-1 ECD, respectively. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1:PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Finally, blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12, 13).

References